Previous 10 | Next 10 |
FLORHAM PARK, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has been granted Small ...
La Jolla Pharmaceutical (NASDAQ: LJPC ) -24% . More news on: La Jolla Pharmaceutical Company, Arcus Biosciences, Inc., Mitcham Industries, Inc., Stocks on the move, , Read more ...
Mmtec (NASDAQ: MTC ) +168% on FY results . More news on: Mmtec, Inc., Sky Solar Holdings, Ltd., Cellectar Biosciences, Inc., Stocks on the move, , Read more ...
The FDA grants Fast Track status to Cellectar Biosciences (NASDAQ: CLRB ) CLR 131 application for patients with lymphoplasmacytic lymphoma (LPL)/ Waldenstrom’s macroglobulinemia (WM) in patients who have received at least two prior lines of therapy. More news on: Cellectar Biosci...
FLORHAM PARK, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration...
FLORHAM PARK, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the European Patent Office ...
Gainers: Cellect Biotechnology (NASDAQ: APOP ) +77% . More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., Remark Holdings, Inc., Stocks on the move, , Read more ...
The need for capital continues apace for healthcare companies as they deal with COVID-19 disruptions. More news on: Check-Cap Ltd., Cellectar Biosciences, Inc., BioTelemetry, Inc., Healthcare stocks news, , Read more ...
Cellectar Biosciences (NASDAQ: CLRB ) is 13.3% lower in light postmarket trading after filing to offer $17.5M worth of shares and prefunded warrants. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Cellectar Biosciences (NASDAQ: CLRB ): Q1 GAAP EPS of -$0.42 misses by $0.07 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences,...
Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develop...